江西天新药业股份有限公司 关于会计师事务所 2023 年度履职情况的评估报告 江西天新药业股份有限公司（以下简称"公司"）聘请中汇会计师事务所 （特殊普通合伙）（以下简称"中汇会计师事务"）作为公司 2023 年度财务报 告审计机构和内部控制审计机构。现中汇会计师事务所已完成 2023 年度财务报 告审计和内部控制审计相关工作。根据财政部、国资委及证监会颁布的《国有 企业、上市公司选聘会计师事务所管理办法》，公司对中汇会计师事务所 2023 年年度审计中的履职情况进行了评估。经评估，公司认为，中汇会计师事务所 资质等方面合规有效，履职能够保持独立性，勤勉尽责，公允表达意见。具体 情况如下： 一、 资质条件 （一）会计师事务所基本信息 中汇会计师事务所，于 2013 年 12 月转制为特殊普通合伙，管理总部设立 于杭州，系原具有证券、期货业务审计资格的会计师事务所之一，长期从事证 券服务业务。 上年度末（2023 年 12 月 31 日）合伙人数量：103 人 上年度末（2023 年 12 月 31 日）注册会计师人数：701 人 上年度末（2023 年 12 月 31 日）签署过证券服务业务审计报告的注册会计 ...

Accounting Methods and Revenue Recognition - The company adjusts the accounting method for remaining equity after losing control of a subsidiary, either using the equity method or recognizing the difference between fair value and book value as current profit or loss[1] - Revenue from export sales is recognized based on the trade terms, with different recognition points for various trade settlement methods such as CIF, FOB, and DDP[5] - Revenue from domestic sales is recognized upon delivery to the customer's specified location and customer confirmation of receipt[9] Asset Management and Impairment - Construction in progress is recognized when economic benefits are likely to flow in and costs can be reliably measured, and is transferred to fixed assets upon reaching the intended usable state[2] - The company reviews the useful life and amortization method of finite-lived intangible assets annually, adjusting estimates and recognizing impairment if future economic benefits are no longer expected[4] - The company assesses impairment of assets related to contract costs, recognizing impairment losses if the carrying amount exceeds the expected remaining consideration minus estimated costs[10] - The company's intangible assets have a book value of 192,311,293.45 RMB at the end of the period, with a cumulative amortization of 20,669,830.54 RMB[34] - The company's engineering materials have a book value of 82,350,552.80 RMB at the end of the period, with a provision for impairment of 721,797.20 RMB[28] Government Grants and Subsidies - Government grants are recognized upon receipt, with specific criteria for recognizing grants based on expected amounts and compliance with fiscal support policies[7] - Government subsidies are recognized as deferred income and amortized over the useful life of related assets, with any remaining balance transferred to profit or loss upon disposal of the assets[11] - The company's deferred tax assets at the end of the period were RMB 85,304,542.97, with a significant portion coming from government subsidies of RMB 58,661,705.01[39][40] - Total government subsidies received increased to 138,021,872.10 RMB from 29,916,370.85 RMB, a significant growth of 361.4%[67] Financial Assets and Liabilities - The company holds no financial assets measured at fair value through profit or loss as of the reporting period, compared to RMB 230 million at the beginning of the period[13] - Bank acceptance bills amounted to RMB 50.49 million at the end of the period, all of which were not derecognized[14] - The balance of bank acceptance notes was RMB 53.29 million at the end of the period, with no bad debt provision[15] - The company's financial assets and liabilities not measured at fair value have a book value close to their fair value[169] - The fair value of receivables financing at the end of the period is RMB 3,292,184.01, classified under Level 2 fair value measurement[166] Inventory and Cost Management - Inventory increased from RMB 4.56 million to RMB 13.67 million, with significant growth in work-in-progress and finished goods[20] - Raw materials inventory decreased from RMB 83.18 million to RMB 39.66 million, while finished goods inventory increased from RMB 198.48 million to RMB 307.34 million[23] - The total inventory balance at the end of the period was RMB 492.63 million, with a provision for inventory impairment of RMB 13.67 million[23] - Operating costs decreased by 19.71% to RMB 1,161,708,799.37, primarily due to lower raw material prices and reduced manufacturing expenses[183][184] Project Investments and Progress - The budget for the Vitamin B5 project is 460,021,300 RMB, with a cumulative investment of 75.44% of the budget, and the project progress is 75.44%[25] - The Vitamin A project has a budget of 781,291,500 RMB, with a cumulative investment of 25.40% of the budget, and the project progress is 25.40%[25] - The Enterprise Research Institute project has a budget of 128,865,500 RMB, with a cumulative investment of 69.20% of the budget, and the project progress is 69.20%[25] - The fine chemical project has a budget of 500,000,000 RMB, with a cumulative investment of 2.95% of the budget, and the project progress is 2.95%[25] - The Le Ping Industrial Park cogeneration project has a budget of 350,000,000 RMB, with a cumulative investment of 12.07% of the budget, and the project progress is 12.07%[25] - The other fine chemical product project has a budget of 3,690,000,000 RMB, with a cumulative investment of 5.80% of the budget, and the project progress is 5.80%[25] - The Qingtongxia Industrial Park thermal power island project has a budget of 1,464,730,000 RMB, with a cumulative investment of 2.71% of the budget, and the project progress is 2.71%[25] - The total budget for all projects is 7,374,908,300 RMB, with a cumulative investment of 342,940,892.04 RMB[25] Financial Performance and Metrics - The company's total revenue for the year 2023 was RMB 1,881,993,019.35, with a cost of RMB 1,161,708,799.37, resulting in a gross profit of RMB 720,284,219.98[50] - B-vitamins contributed the majority of the revenue, generating RMB 1,650,309,734.61, with a cost of RMB 958,705,177.48[52] - Domestic sales accounted for RMB 782,140,234.10, while international sales contributed RMB 1,099,852,785.25[52] - The company's net profit for the current period was 475,853,298.64 RMB, a decrease from the previous period's 622,115,124.53 RMB[98] - Revenue for 2023 was 1,881,993,019.35 yuan, a decrease of 18.34% compared to the previous year[120] - Net profit attributable to shareholders was 475,853,298.64 yuan, down 23.51% year-on-year[120] - Operating cash flow increased by 20.21% to 729,212,499.59 yuan[120] - Basic earnings per share (EPS) decreased by 27.81% to 1.09 yuan per share[121] - Weighted average return on equity (ROE) dropped by 10.23 percentage points to 11.55%[121] Cash Flow and Financing Activities - The company's cash and cash equivalents increased by 238,239,548.75 RMB, reaching a total of 2,307,768,991.53 RMB at the end of the period[98] - The company's short-term borrowing increased by 100,000,000.00 RMB, with a total of 100,072,222.22 RMB at the end of the period[96] - The company's total investment in financial products was 1,798,000,000.00 RMB, an increase from the previous period's 1,622,010,000.00 RMB[94] - The company's total cash outflow related to leasing activities was 3,383,139.22 RMB[105] - The company's total cash outflow related to financing activities was 3,171,139.22 RMB, a significant decrease from the previous period's 30,315,099.62 RMB[95] - The company's total cash outflow related to investment activities was 1,798,000,000.00 RMB, an increase from the previous period's 1,622,010,000.00 RMB[94] - The company's total cash outflow related to operating activities was 729,212,499.59 RMB, an increase from the previous period's 606,613,170.14 RMB[98] - The company's total cash outflow related to the payment of dividends was 310,823,800.00 RMB[96] - The company's total cash outflow related to the payment of IPO issuance fees was 26,602,479.62 RMB in the previous period[95] Expenses and Costs - Total management expenses decreased to 136,349,813.27 RMB from 144,180,344.74 RMB, a reduction of 5.4%[53] - R&D expenses increased to 111,964,592.30 RMB from 89,462,842.32 RMB, a growth of 25.1%[54] - Government subsidies decreased to 47,390,378.61 RMB from 53,254,038.41 RMB, a reduction of 11.0%[55] - Investment income from bank financial products decreased to 2,454,302.84 RMB from 4,653,541.60 RMB, a reduction of 47.3%[56] - Interest income increased significantly to 74,460,498.56 RMB from 16,251,609.72 RMB, a growth of 358.2%[56] - Credit impairment losses slightly decreased to 3,159,494.22 RMB from 3,233,939.87 RMB, a reduction of 2.3%[59] - Asset impairment losses increased to -12,363,832.71 RMB from -4,157,876.36 RMB, a significant increase in losses[60] - Current income tax expense increased to 111,841,440.48 RMB from 100,786,018.29 RMB, a growth of 11.0%[63] - Total employee compensation increased to 80.16 million yuan from 74.19 million yuan, a rise of 8.05%[107] - Direct material costs rose to 7.26 million yuan from 5.29 million yuan, an increase of 37.25%[107] - Depreciation and amortization expenses surged to 12.35 million yuan from 2.98 million yuan, a significant jump of 315.08%[107] - Other expenses increased to 12.19 million yuan from 7.01 million yuan, up by 73.96%[107] - Total expenses for the period amounted to 111.96 million yuan, up from 89.46 million yuan, a 25.15% increase[107] Market and Industry Analysis - The vitamin industry faced challenges with slowing global economic growth and increased competition[128] - The company achieved domestic registration approval for folic acid raw materials and obtained EU export certification for Vitamin D3 raw materials[129] - The company completed multiple quality system expansion certifications, including ISO22000 for cholesterol and FAMI-QS certification for Vitamin A acetate and 25-hydroxy Vitamin D3[129] - R&D expenses continued to grow rapidly, driving continuous improvement in production levels[130] - The company is steadily advancing projects such as Vitamin A, Vitamin B5, and Ningxia Tianxin, ensuring sustainable development[130] - China's vitamin production in 2023 is expected to reach 434,000 tons, a 4.0% year-on-year increase, accounting for 84.4% of global production[134] - The Chinese vitamin market value in 2023 is projected to be $3.72 billion, a 16.4% year-on-year decrease[134] - The company holds a leading global market share in Vitamin B6 and Vitamin B1, and is in the top tier for biotin and folic acid products[135] - The company has established a strong global competitiveness in B-group vitamins, including Vitamin B6, Vitamin B1, biotin, and folic acid[136] - The company's ABL product, used in pesticide intermediates and Vitamin B1, achieved external sales in 2022 and further expanded in 2023[136] - Vitamin business accounted for 96.30% of the company's main business revenue in 2023, being the primary factor affecting performance fluctuations[141] - Overall downstream demand for vitamins was weak in 2023, leading to increased competitive pressure on the supply side and suppressed prices, contributing to the company's performance decline[141] Corporate Governance and Compliance - The company established Tianxin International Holdings (Hong Kong) Limited in March 2023 with a registered capital of 10,000 HKD[109] - As of December 31, 2023, Tianxin International Holdings (Hong Kong) Limited reported a net loss of 92,783.10 yuan[109] - The company's subsidiary, Ningxia Tianxin Pharmaceutical Co., Ltd., transferred 10,000 yuan of equity in Qingtongxia Tianxin Dingheng Heating Power Co., Ltd., reducing its indirect ownership from 100% to 99.75%[113] - The company's stock is listed on the Shanghai Stock Exchange under the ticker symbol 603235[116] - The company's auditor is Zhonghui Certified Public Accountants, and its continuous supervision sponsor is CITIC Securities[117] - The company's environmental management system is established and maintained in accordance with ISO14001 standards, emphasizing green development and circular economy[143][147] - The company has a comprehensive sales and service network centered in Shanghai, covering Asia, Europe, North America, South America, Oceania, and Africa[148] - The company has obtained various certifications, including FAMI-QS, ISO22000, BRC, Halal, Kosher, and certifications from regulatory bodies in China, the EU, the US, and Japan, ensuring access to high-end markets[149] Debt and Liabilities - The company's debt-to-asset ratio increased to 16.84% as of December 31, 2023, compared to 13.29% in the previous year[163] - Short-term borrowings: RMB 10,104.00 (within one year)[161] - Accounts payable: RMB 12,663.93 (within one year)[161] - Other payables: RMB 857.85 (within one year)[161] - Non-current liabilities due within one year: RMB 312.37[161] - Lease liabilities: RMB 530.04 (total)[162] - Total financial liabilities and contingent liabilities: RMB 25,611.19 (current period) vs RMB 12,783.00 (previous period)[162] - The company's other payables decreased from RMB 10,548,296.39 at the beginning of the period to RMB 8,578,504.58 at the end of the period[173] - The company's non-bank acceptance bills endorsed but not yet due decreased from RMB 60,012,793.35 at the beginning of the period to RMB 50,489,814.34 at the end of the period[177] - The company's government grants increased from RMB 306,156,569.99 at the beginning of the period to RMB 390,788,063.48 at the end of the period, with an increase of RMB 115,419,200.00 and a decrease of RMB 30,787,706.51 during the period[180] - The company's lease liabilities due within 1 year decreased from RMB 3,419,674.54 at the beginning of the period to RMB 3,123,735.24 at the end of the period[176] - The company's long-term payables increased from RMB 4,646,387.50 at the beginning of the period to RMB 5,095,912.47 at the end of the period[178] - The company's prepaid taxes to be transferred decreased from RMB 1,613,296.80 at the beginning of the period to RMB 1,016,999.16 at the end of the period[177] - The company's deposit and guarantee liabilities increased from RMB 175,000.00 at the beginning of the period to RMB 225,000.00 at the end of the period[175] Related Party Transactions - The company's total related party transactions amounted to RMB 3,006.56 million, with the majority coming from sales to related parties at RMB 2,105.95 million[47] - The company's subsidiaries and related parties include Zhejiang Tianxin Pharmaceutical Co., Ltd., Zhejiang Xinweishi Biotechnology Co., Ltd., and Shanghai Newrite Biotechnology Co., Ltd., among others[171] Research and Development - R&D expenses increased by 25.15% to RMB 111,964,592.30, reflecting increased investment in research and development[183] - The company's R&D expense ratio continued to increase during the reporting period, with projects such as Vitamin B5, Vitamin A, and Ningxia Tianxin progressing as planned[142] - The company's production sites have passed FDA certification, and Vitamin B6 and Vitamin B1 (hydrochloride) have obtained FDA DMF filings[143] Sales and Distribution - The company's sales model is primarily direct sales, with distributors handling wholesale or retail[140] - Main business revenue for 2023 was RMB 1,851,390,100, a decrease of 17.83%, mainly due to lower vitamin product prices[185] - Main business costs for 2023 were RMB 1,135,447,100, a decrease of 18.98%, driven by lower raw material prices and reduced manufacturing expenses[185] - Contract liabilities decreased to RMB 21,098,771.55 from RMB 23,341,621.74, indicating a reduction in prepayments from customers[196] Taxation and Deferred Taxes - Deferred tax assets and liabilities are recognized based on temporary differences between book value and tax base, with certain exceptions for transactions not affecting accounting profit or taxable income[8] - The company's internal transactions resulted in unrealized profits of RMB 126,804,672.87, with deferred tax assets of RMB 19,020,700.93[40] - The company's bad debt provision decreased by RMB 3,155,511.19, resulting in a deferred tax asset reduction of RMB 471,116.80[39] - The company's unconfirmed deferred tax assets increased by RMB 21,338,495.70, primarily due to deductible losses of RMB 17,651,718.49[45] - Deferred tax liabilities at the end of the period were RMB 4,179,272.04, primarily due to accelerated depreciation of fixed assets amounting to RMB 2,278,177.38[42] Other Financial Metrics - The total balance of deposits, guarantees, and other receivables decreased from RMB 4.27 million to RMB 2.44 million year-over-year[18] - The provision for bad debts decreased by RMB 1.5 million, resulting in a year-end balance of RMB 738,295.84[21] - The company's long-term prepaid expenses decreased by RMB 1,385,837.04, with the hazardous waste treatment center opening fee being the largest component at RMB 8,021,289.

江西天新药业股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603235 证券简称：天新药业 公告编号：2024-024 本次会计政策变更是江西天新药业股份有限公司（以下简称"公司"）根 据中华人民共和国财政部（以下简称"财政部"）发布的相关会计准则解释进行 的相应变更，不会对当期和会计政策变更之前公司总资产、负债总额、净资产及 净利润产生重大影响。 （二）变更后采用的会计政策 本次会计政策变更是公司根据财政部发布的解释 16 号的相关规定执行，其 他未变更部分仍按照财政部前期颁布的《企业会计准则——基本准则》和各项具 体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他相关规定 执行。 （三）会计政策变更的内容 本次会计政策变更，是公司根据国家统一的会计制度要求进行的变更， 无需提交公司董事会、监事会和股东大会审议。 一、本次会计政策变更概述 财政部于 2022 年 11 月 30 日发布了《关于印发<企业会计准则解释第 16 号> 的通知》（财会〔2 ...

公司代码：603235 公司简称：天新药业 江西天新药业股份有限公司 2023 年度内部控制评价报告 江西天新药业股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能 ...

证券代码：603235 证券简称：天新药业 公告编号：2024-012 江西天新药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定：回购股份期间，上市公司应当在每个月的前 3 个交 易日内公告截至上月末的回购进展情况。现将公司回购股份情况公告如下： 2024 年 3 月，公司未实施股份回购。 截至 2024 年 3 月月底，公司已累计回购股份 1,368,268 股，已回购股份占公 司总股本的比例为 0.3125%，回购的最高价格为 22.61 元/股，最低价格为 19.17 元 /股，已支付的总金额为 28,417,490.56 元（不含交易费用）。 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出回 购决策并予以实 ...

一、 本次签字会计师变更的基本情况 证券代码：603235 证券简称：天新药业 公告编号：2024-011 江西天新药业股份有限公司 关于变更签字会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江西天新药业股份有限公司（以下简称"公司"）于 2023 年 4 月 21 日召开 的第二届董事会第十三次会议，审议通过了《关于公司续聘 2023 年度审计机构 的议案》，同意公司继续聘请中汇会计师事务所（特殊普通合伙）（以下简称"中 汇会计师事务所"）为公司 2023 年年度财务报告审计机构和内部控制审计机构， 并提交公司 2022 年年度股东大会审议，具体内容详见公司于 2023 年 4 月 22 日 披露的《关于续聘会计师事务所的公告》（公告编号：2023-009）。公司于 2023 年 5 月 12 日，召开 2022 年年度股东大会，审议通过了《关于公司续聘 2023 年 度审计机构的议案》，具体内容详见公司于 2023 年 5 月 13 日披露的《2022 年 年度股东大会决议公告》（公告编号：2023-014 ...

证券代码：603235 证券简称：天新药业 公告编号：2024-010 江西天新药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至上月末的回购进展情况：2024 年 2 月，江西天新药业股份有限公司 （以下简称"公司"）通过集中竞价交易方式已累计回购公司股份 1,368,268 股，已回购股份占公司总股本的比例为 0.3125%，回购的最高 价格为 22.61 元/股，最低价格为 19.17 元/股，已支付的总金额为 28,417,490.56 元（不含交易费用）。截至 2024 年 2 月月底，公司已累计 回购股份 1,368,268 股，已回购股份占公司总股本的比例为 0.3125%，回 购的最高价格为 22.61 元/股，最低价格为 19.17 元/股，已支付的总金额 为 28,417,490.56 元（不含交易费用）。 一、回购方案的基本情况 2024 年 1 月 22 日，公司第三届董事会第二次会议审议通过了《关于以集中 竞价交易方式回 ...

证券代码：603235 证券简称：天新药业 公告编号：2024-009 江西天新药业股份有限公司 具体内容详见公司于 2024 年 1 月 23 日和 2024 年 1 月 30 日刊登在上海证 券交易所（www.sse.com.cn）及公司指定披露媒体上的《关于以集中竞价交易方 本次回购截至上月末的回购进展情况：截至 2024 年 1 月 31 日，江西天新 药业股份有限公司（以下简称"公司"）尚未通过集中竞价交易方式回购公 司股份。 本次回购方案的实施情况：2024 年 2 月 1 日，公司通过集中竞价交易方式 首次回购公司股份135,400股，已回购股份占公司总股本的比例为0.0309%， 回购的最高价格为 20.87 元/股，最低价格为 20.17 元/股，已支付的总金额 为 2,767,019.00 元（不含交易费用）。 式回购股份方案的公告》（公告编号：2024-003）和《关于以集中竞价交易方式 回购股份的回购报告书》（公告编号：2024-008）。 二、首次回购股份情况及截至上月末的回购进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定 ...

江西天新药业股份有限公司 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、本次回购股份期限内，若公司股票价格持续超出本次回购方案披露的价 格上限，可能存在本次回购方案无法实施或只能部分实施的风险； 证券代码：603235 证券简称：天新药业 公告编号：2024-008 2、若公司生产经营、财务状况、外部客观情况发生重大变化，或其他导致 公司董事会决定终止本次回购的事项发生，可能存在本次回购方案无法顺利实施 的风险； 回购股份的用途：用于员工持股计划或股权激励 回购股份的资金总额：不低于人民币 6,000 万元（含），不超过人民币 12,000 万元（含） 回购期限：自江西天新药业股份有限公司（以下简称"公司"）董事会审 议通过本次回购方案之日起 12 个月内 回购价格：不超过 33.00 元/股（含），该价格不高于公司董事会通过回购 决议前 30 个交易日公司股票交易均价的 150% 回购资金来源：公司自有资金 相关股东是否存在减持计划：经公司问询，截至本次回购方 ...

二、 董事会会议审议情况 （一）审议通过《关于以集中竞价交易方式回购股份方案的议案》 证券代码：603235 证券简称：天新药业 公告编号：2024-005 江西天新药业股份有限公司 第三届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 董事会会议召开情况 江西天新药业股份有限公司（以下简称"公司"）第三届董事会第二次会议于 2024 年 1 月 22 日在公司会议室以现场结合通讯表决的方式召开。本次会议通知 已于 2024 年 1 月 17 日以电子邮件及专人送达等方式送达全体董事。本次会议应 到董事 9 人，实到董事 9 人。会议由公司董事长许江南先生主持，公司监事、高 级管理人员列席会议。本次会议的召开符合《中华人民共和国公司法》《江西天 新药业股份有限公司章程》等有关规定，会议决议合法有效。 （三）审议通过《关于制定公司<独立董事专门会议工作制度>的议案》 该议案同意票数为 9 票，反对票数为 0 票，弃权票数为 0 票。 （四）审议通过《关于修订公司董事会各专门委员会实施细则的议案》 ...